American Journal of Kidney Diseases
Volume 47, Issue 1 , Pages 24-36 , January 2006

Evidence-Based Systematic Literature Review of Hemoglobin/Hematocrit and All-Cause Mortality in Dialysis Patients

  • Nataliya Volkova, MPH
    • ,
  • Lenore Arab, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Lenore Arab, PhD, 650 Charles E. Young Drive S, Rm 73-265 CHS, Los Angeles, CA, 90095-1772

Received 11 July 2005 ,Accepted 7 September 2005.

References 

  1. National Kidney Foundation . K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease (Update 2000) . Am J Kidney Dis . 2001;37(suppl 1):S182–S238
  2. Strippoli GF , Manno C , Schena FP , Craig JC . Haemoglobin and haematocrit targets for the anaemia of chronic renal disease . Cochrane Database Syst Rev . 2003; (Online) CD003967
  3. Bennett WM . A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease . J Am Soc Nephrol . 1991;1:990–998
  4. Mocks J . Cardiovascular mortality in haemodialysis patients treated with epoetin beta—A retrospective study . Nephron . 2000;86:455–462
  5. Bahlmann J , Schoter KH , Scigalla P , et al.   Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment (A controlled study) . Contrib Nephrol . 1991;88:90–106
  6. Klinkmann H , Wieczorek L , Scigalla P . Adverse events of subcutaneous recombinant human erythropoietin therapy (Results of a controlled multicenter European study) . Artif Organs . 1993;17:219–225
  7. Foley RN , Parfrey PS , Morgan J , et al.   Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy . Kidney Int . 2000;58:1325–1335
  8. Besarab A , Bolton WK , Browne JK , et al.   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin . N Engl J Med . 1998;339:584–590
  9. Furuland H , Linde T , Ahlmen J , Christensson A , Strombom U , Danielson BG . A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients . Nephrol Dial Transplant . 2003;18:353–361
  10. Avram MM , Blaustein D , Fein PA , Goel N , Chattopadhyay J , Mittman N . Hemoglobin predicts long-term survival in dialysis patients (A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin) . Kidney Int . 2003;(Suppl 87):S6–S11
  11. Collins AJ , Li S , St Peter W , et al.   Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% . J Am Soc Nephrol . 2001;12:2465–2473
  12. Culp K , Flanigan M , Lowrie EG , Lew N , Zimmerman B . Modeling mortality risk in hemodialysis patients using laboratory values as time-dependent covariates . Am J Kidney Dis . 1996;28:741–746
  13. Degoulet P , Legrain M , Reach I , et al.   Mortality risk factors in patients treated by chronic hemodialysis (Report of the Diaphane Collaborative Study) . Nephron . 1982;31:103–110
  14. Fernandez-Reyes MJ , Alvarez-Ude F , Sanchez R , et al.   Inflammation and malnutrition as predictors of mortality in patients on hemodialysis . J Nephrol . 2002;15:136–143
  15. Fink J , Blahut S , Reddy M , Light P . Use of erythropoietin before the initiation of dialysis and its impact on mortality . Am J Kidney Dis . 2001;37:348–355
  16. Foley RN , Parfrey PS , Harnett JD , Kent GM , Murray DC , Barre PE . The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease . Am J Kidney Dis . 1996;28:53–61
  17. Harnett JD , Kent GM , Foley RN , Parfrey PS . Cardiac function and hematocrit level . Am J Kidney Dis . 1995;25(suppl 1):S3–S7
  18. Ifudu O , Uribarri J , Rajwani I . Low hematocrit may connote a malnutrition/inflammation syndrome in hemodialysis patients . Dial Transplant . 2002;31:845–878
  19. Li S , Collins AJ . Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients . Kidney Int . 2004;65:626–633
  20. Li S , Foley RN , Collins AJ . Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States . Kidney Int . 2004;65:1864–1869
  21. Locatelli F , Conte F , Marcelli D . The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity—The experience of the Lombardy Dialysis Registry . Nephrol Dial Transplant . 1998;13:1642–1644
  22. Locatelli F , Pisoni RL , Combe C , et al.   Anaemia in haemodialysis patients of five European countries (Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)) . Nephrol Dial Transplant . 2004;19:121–132
  23. Lowrie EG , Curtin RB , LePain N , Schatell D . Medical Outcomes Study Short Form-36 (A consistent and powerful predictor of morbidity and mortality in dialysis patients) . Am J Kidney Dis . 2003;41:1286–1292
  24. Ma JZ , Ebben J , Xia H , Collins AJ . Hematocrit level and associated mortality in hemodialysis patients . J Am Soc Nephrol . 1999;10:610–619
  25. Madore F , Lowrie EG , Brugnara C , et al.   Anemia in hemodialysis patients (Variables affecting this outcome predictor) . J Am Soc Nephrol . 1997;8:1921–1929
  26. Ofsthun N , Labrecque J , Lacson E , Keen M , Lazarus JM . The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients . Kidney Int . 2003;63:1908–1914
  27. Thompson NM , Atkins RC , Humphery TJ , Agar JM , Scott DF . Continuous ambulatory peritoneal dialysis (CAPD) (An established treatment for end stage renal failure) . Aust N Z J Med . 1983;13:489–496
  28. Warady BA , Ho M . Morbidity and mortality in children with anemia at initiation of dialysis . Pediatr Nephrol . 2003;18:1055–1062
  29. Xue JL , St Peter WL , Ebben JP , Everson SE , Collins AJ . Anemia treatment in the pre-ESRD period and associated mortality in elderly patients . Am J Kidney Dis . 2002;40:1153–1161

 N.V. and L.A. were employed by Amgen Inc at the time the work started, and both subsequently left the company. Research support therefore was received in part as salary, but no other funding of this project has been received from Amgen subsequently. The work continued at University of California at Los Angeles (L.A.) and Rollins School of Public Health, Emory University (N.V.).

 Originally published online as doi:10.1053/j.ajkd.2005.09.007 on November 14, 2005.

PII: S0272-6386(05)01350-8

doi: 10.1053/j.ajkd.2005.09.007

American Journal of Kidney Diseases
Volume 47, Issue 1 , Pages 24-36 , January 2006

Article Tools

* Image Usage & Resolution